N-Acetyl Cysteine (NAC) for Stage IV Cancer
Also known as: NAC, Acetylcysteine
NAC's dual role — chemoprotective for normal tissue while potentially sensitizing certain tumors — makes it a complex adjunctive agent.
Mechanism of Action
NAC protects normal cells from chemotherapy/radiation oxidative damage by restoring glutathione. In certain cancers, it may inhibit tumor growth by modulating NF-κB, reducing VEGF, and enhancing immune surveillance. However, NAC may protect some tumors too.
General mechanism: Cysteine prodrug for glutathione synthesis. Direct ROS scavenger. NMDA receptor modulator. NF-κB inhibitor.
Current Evidence
Clinical evidence mixed. Protective against cisplatin nephrotoxicity. Controversy about whether antioxidants protect tumors during treatment. Context-dependent effects.
Clinical Status: Used clinically for chemoprotection. Cancer-specific evidence mixed and context-dependent.
Safety Profile
Very safe. GI effects common with oral use. IV administration well-established (acetaminophen protocol). Rare: bronchospasm in asthmatics.
Key Research Questions
- In which cancer types does NAC enhance vs interfere with treatment?
- Can NAC reduce treatment toxicity without compromising efficacy?